People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. | — | Biotechnology | Series D+ | $225.9M | $2.2B | 2024 |
Jason I. Pitts at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jason I. Pitts on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James I. Healy | 1 | 7 |
| Daphne Zohar | 1 | 4 |
| Eric Elenko | 1 | 4 |
| Steven Paul | 1 | 3 |
| Eric Green | 1 | 2 |
| Lana Gladstein | 1 | 1 |
| Antony Loebel | 1 | 1 |
| David I. Wheadon | 1 | 1 |
| Robert I. Nelsen | 1 | 1 |
| Bharatt I. Chowrira | 1 | 1 |
| Denice I. Torres | 1 | 1 |
| Michael Chen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.